Department of Pharmacy, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Haishu District, Ningbo, 315010, Zhejiang, China.
Mol Cell Biochem. 2024 Aug;479(8):1909-1923. doi: 10.1007/s11010-023-04821-0. Epub 2023 Aug 5.
Cardiovascular disease, especially myocardial infarction, is a serious threat to human health. Many drugs currently used cannot achieve the desired therapeutic effect due to the lack of selectivity. With the in-depth understanding of the role of microRNA (miRNA) in cardiovascular disease and the wide application of nanotechnology, loading drugs into nanoparticles with the help of nano-delivery system may have a better effect in the treatment of cardiomyopathy. In this review, we highlight the latest research on miRNAs in the treatment of cardiovascular disease in recent years and discuss the possibilities and challenges of using miRNA to treat cardiomyopathy. Secondly, we discuss the delivery of miRNA through different nano-carriers, especially inorganic, polymer and liposome nano-carriers. The preparation of miRNA nano-drugs by encapsulating miRNA in these nano-materials will provide a new treatment option. In addition, the research status of miRNA in the treatment of cardiomyopathy based on nano-carriers is summarized. The use of this delivery tool cannot only realize therapeutic potential, but also greatly improve drug targeting and reduce side effects.
心血管疾病,特别是心肌梗死,严重威胁人类健康。由于缺乏选择性,目前许多药物并不能达到理想的治疗效果。随着对 microRNA(miRNA)在心血管疾病中作用的深入了解以及纳米技术的广泛应用,借助纳米递药系统将药物载入纳米颗粒中可能在治疗心肌病方面具有更好的效果。在这篇综述中,我们重点介绍了近年来 miRNA 在心血管疾病治疗方面的最新研究进展,并讨论了利用 miRNA 治疗心肌病的可能性和挑战。其次,我们讨论了通过不同的纳米载体(特别是无机、聚合物和脂质体纳米载体)来递送 miRNA。通过将 miRNA 封装在这些纳米材料中制备 miRNA 纳米药物,将为治疗提供新的选择。此外,还总结了基于纳米载体的 miRNA 在治疗心肌病方面的研究现状。使用这种递药工具不仅可以实现治疗潜力,还可以大大提高药物靶向性,减少副作用。